Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
24 pending office actions • 17 art units • 24 examiners • 0 of 24 (0%) have an AI response strategy ready • 20 patents granted in the last 365 days
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. has 24 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 24 actions are assigned to 24 distinct examiners, resulting in a one to one ratio of examiners to pending cases. The portfolio is spread across 17 distinct art units, indicating significant technical diversity. This distribution ensures that the 24 pending office actions are reviewed by a wide variety of experts at the patent office.
The busiest examiner is WARD, PAUL V, who has 1 pending office action. Because each of the 24 distinct examiners has only 1 pending action, the workload is perfectly distributed across the 24 cases. The 17 distinct art units indicate that the company's 24 pending office actions cover a wide array of technical fields within the biotechnology and pharmaceutical sectors. By engaging 24 distinct examiners across 17 distinct art units, the company avoids concentration risk and benefits from a broad range of examiner feedback on its 24 pending office actions. This decentralized approach is particularly useful in the complex Biotechnology & Pharmaceuticals technology area.
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (12%) |
| §103 only | 5 (21%) |
| §102 only | 2 (8%) |
| §112 only | 2 (8%) |
| Double-patenting + other | 1 (4%) |
| Multi-statute (no §101) | 11 (46%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| ARMATO JR, DENNIS IGNATIUS | 1 | 42.9% | +80.0% |
| MILLER, DALE R | 1 | 62.4% | +17.5% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.5% | +49.1% |
| O'HERN, BRENT T | 1 | 78.5% | +19.8% |
| WRIGHT, ERIC BRANDON | 1 | — | — |
| SEITZ, ANTHONY JOSEPH | 1 | 68.3% | +27.0% |
| TRIVISONNO, ANGELO | 1 | 53.0% | +25.8% |
| HOFFA, ANGELA MARIE | 1 | 67.6% | +28.3% |
| HABTE, KAHSAY | 1 | 85.0% | +7.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554199 | THERAPEUTIC MODALITIES FOR INHIBITING PANCREATIC BETA CELL IMPAIRMENT AND TREATING DIABETES | HABTE, KAHSAY | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259836 | STABLE EFFICIENT COSMETIC PREPARATIONS | CHANG, KYUNG SOOK | 160d overdue |
| 18007152 | INJECTION MOLDING OF MEAT-LIKE FOOD PRODUCTS | BECKER, DREW E | 119d overdue |
| 17765625 | LIPOSOMAL CANNABINOIDS AND USES THEREOF | MITCHELL, EDWIN COLEMAN | 98d overdue |
| 18040810 | CELLULOSE BINDING DOMAIN (CBD) CELL EFFECTOR PROTEIN (CEP) CHIMERA, FOR THE TISSUE ENGINEERING | LEE, JAE W | 15d |
| 18624587 | PROTECTIVE COATING FOR PLANTS AND POSTHARVEST PLANT MATTER | O'HERN, BRENT T | 75d |
| 18559809 | PEROVSKITE COMPOSITIONS AND USES THEREOF IN PHOTOVOLTAIC DEVICES | TRIVISONNO, ANGELO | 83d |
| 18833008 | METAP2 INHIBITORS AND USES THEREOF | WARD, PAUL V | — |
| 18746141 | NOMADIC BACTERIA AND USES THEREOF | ARMATO JR, DENNIS IGNATIUS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286618 | MRI BASED SYSTEM AND METHOD FOR DETECTING IRON-RELATED ENTITIES IN A REGION OF INTEREST | HOFFA, ANGELA MARIE | 77d overdue |
| 18624587 | PROTECTIVE COATING FOR PLANTS AND POSTHARVEST PLANT MATTER | O'HERN, BRENT T | 75d |
| 18559809 | PEROVSKITE COMPOSITIONS AND USES THEREOF IN PHOTOVOLTAIC DEVICES | TRIVISONNO, ANGELO | 83d |
| 18746141 | NOMADIC BACTERIA AND USES THEREOF | ARMATO JR, DENNIS IGNATIUS | — |
| 18718915 | CARDIAC STEROID DERIVATIVES | MILLER, DALE R | — |
| 18699294 | ARYLATED FENCHONE DERIVATIVES, COMPOSITIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | TOWNSLEY, SARA ELIZABETH | — |
| 18290220 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | SEITZ, ANTHONY JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1793 | 2 |
| 1632 | 2 |
| 1624 | 2 |
| 1613 | 2 |
| 1651 | 1 |
| 1622 | 1 |
| 1629 | 1 |
| 1722 | 1 |
| 3799 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18833008 | METAP2 INHIBITORS AND USES THEREOF | WARD, PAUL V | — | §102§112 | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18746141 | NOMADIC BACTERIA AND USES THEREOF | ARMATO JR, DENNIS IGNATIUS | 1651 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18718915 | CARDIAC STEROID DERIVATIVES | MILLER, DALE R | — | §102§103 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18699294 | ARYLATED FENCHONE DERIVATIVES, COMPOSITIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | TOWNSLEY, SARA ELIZABETH | 1622 | §102§103§112 | Non-Final OA | — | Pending | Apr 07, 2024 |
| 18624587 | PROTECTIVE COATING FOR PLANTS AND POSTHARVEST PLANT MATTER | O'HERN, BRENT T | 1793 | §102§103§112 | Non-Final OA | 75d | Pending | Apr 02, 2024 |
| 18598152 | CARDIAC ORGANOID AND ANTI-ELECTRO-MITOCHONDRIAL DESYNCHRONIZATION THERAPY | WRIGHT, ERIC BRANDON | 1632 | §101§102 | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18290220 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | SEITZ, ANTHONY JOSEPH | 1629 | §102 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18559809 | PEROVSKITE COMPOSITIONS AND USES THEREOF IN PHOTOVOLTAIC DEVICES | TRIVISONNO, ANGELO | 1722 | §102§103§112 | Final Rejection | 83d | Pending | Nov 09, 2023 |
| 18286618 | MRI BASED SYSTEM AND METHOD FOR DETECTING IRON-RELATED ENTITIES IN A REGION OF INTEREST | HOFFA, ANGELA MARIE | 3799 | §103 | Final Rejection | 77d overdue | Pending | Oct 12, 2023 |
| 18554199 | THERAPEUTIC MODALITIES FOR INHIBITING PANCREATIC BETA CELL IMPAIRMENT AND TREATING DIABETES | HABTE, KAHSAY | 1624 | §102 | Final Rejection | — | Pending | Oct 05, 2023 |
| 18259836 | STABLE EFFICIENT COSMETIC PREPARATIONS | CHANG, KYUNG SOOK | 1613 | §102§103 | Non-Final OA | 160d overdue | Pending | Jun 29, 2023 |
| 18253146 | EXTREMELY FAST SOLID PHASE SYNTHESIS | VARADARAJ, ARCHANA | 1658 | §103DP | Non-Final OA | 14d | Pending | May 16, 2023 |
| 18251427 | MODIFIED CARBON-BASED MATERIALS | HENDRICKSON, STUART L | 1736 | §102§103§112 | Non-Final OA | — | Pending | May 02, 2023 |
| 18020734 | METHOD FOR THE TREATMENT OF WWOX ASSOCIATED DISEASES | BATES, KEENAN ALEXANDER | 1631 | §103 | Non-Final OA | — | Pending | Feb 10, 2023 |
| 18040810 | CELLULOSE BINDING DOMAIN (CBD) CELL EFFECTOR PROTEIN (CEP) CHIMERA, FOR THE TISSUE ENGINEERING | LEE, JAE W | 1656 | §102§103§112 | Non-Final OA | 15d | Pending | Feb 06, 2023 |
| 18007152 | INJECTION MOLDING OF MEAT-LIKE FOOD PRODUCTS | BECKER, DREW E | 1792 | §103§112 | Final Rejection | 119d overdue | Pending | Jan 27, 2023 |
| 18098184 | METHODS OF CULTURING PROBIOTIC BACILLI | TURNER, FELICIA C | 1793 | §103 | Final Rejection | 34d | Pending | Jan 18, 2023 |
| 18004673 | METHODS OF DETERMINING CANCER THERAPY | NEGIN, RUSSELL SCOTT | — | §101§103§112 | Non-Final OA | — | Pending | Jan 08, 2023 |
| 17765625 | LIPOSOMAL CANNABINOIDS AND USES THEREOF | MITCHELL, EDWIN COLEMAN | 1619 | §103§112 | Non-Final OA | 98d overdue | Pending | Mar 31, 2022 |
| 17634414 | PHYTOCANNABINOIDS FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE, DYSLIPIDEMIA, AND TYPE 2 DIABETES | BRAUN, MADELINE E | 1624 | §112 | Non-Final OA | — | Pending | Feb 10, 2022 |
| 17597878 | ANTICANCER AGENTS | CREWS, JARET JAMES | 1691 | §103 | Final Rejection | 70d overdue | Pending | Jan 27, 2022 |
| 17503581 | CONJUGATES OF AUXIN ANALOGS | FAY, ZOHREH ALEMZADEH | 1617 | §112 | Final Rejection | — | Pending | Oct 18, 2021 |
| 17604183 | SELF-EMULSIFYING DRUG DELIVERY SYSTEMS FOR DELIVERY OF LIPOPHILIC COMPOUNDS | BERRIOS, JENNIFER A | 1613 | §103 | Non-Final OA | 25d overdue | Pending | Oct 15, 2021 |
| 17427405 | NEOANTIGENS CREATED BY ABERRANT-INDUCED SPLICING AND USES THEREOF IN ENHANCING IMMUNOTHERAPY | REGLAS, GILLIAN CHELSEA | 1632 | §103§112 | Final Rejection | — | Pending | Jul 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial